GENE ONLINE|News &
Opinion
Blog

Takeda Pharmaceutical
Takeda Signs New Deal with PeptiDream Spending Billions to Develop Neuromuscular Disease Drugs
2021-07-30
FoundationOne CDx Okayed as Companion Diagnostic for Takeda’s Lung Cancer Drug
2021-07-04
Takeda to Pursue Hard-to-Drug Neurodegenerative Disease Targets with BridGene Biosciences
2021-04-01
Japan Lags Behind in COVID-19 Vaccination Goals, Looks to Hasten Approval of Second Vaccine
2021-03-15
After Five Year Oncology Alliance, Takeda Acquires Maverick to Embark on Solid Tumor Quest
2021-03-10
Neurocrine, Takeda Look to Build on Positives Post Luvadaxistat’s Schizophrenia Trial Failure
2021-03-03
Ensoma Enters Gene-Editing Market with $70 Million Funding and Takeda Partnership
2021-02-12
Data-Driven Molecular Engineering Startup Partners with Takeda to Develop Next-Gen Gene Therapies
2021-01-26
Takeda, KSQ Join Forces to Identify NK Cell Targets For Cancer Therapies
2021-01-16
China’s Hasten Biopharmaceutic Acquires Five Non-Core Assets from Japan’s Takeda
2020-12-24
Prometheus Bags $130 Million to Develop Precision Medicines for IBD Treatment
2020-11-10
Takeda Plans to Distribute 50 Million Doses of Moderna’s COVID-19 Vaccine in Japan
2020-11-01
Takeda Collaborates with Arrowhead to Overcome Inherited Disorder via RNAi Therapy
2020-10-10
Takeda Established Capabilities to Engine Cell Therapy Manufacturing
2020-09-18
Takeda to Sell its Japan Consumer Health Business to Blackstone for $2.3B
2020-08-25
1 2 3 4 5
LATEST
ImmunityBio’s ANKTIVA® Granted FDA Approval: Breakthrough IL-15 Receptor Agonist First-in-Class for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
2024-04-24
Takeda, Astellas, and Sumitomo Mitsui Banking Declare Agreement For Early Drug Discovery Program Incubation in Joint Venture
2024-04-23
Ochre Bio Announces Partnership with Boehringer Ingelheim to Develop Novel Regenerative Treatments for Patients with Advanced Liver Disease
2024-04-22
Earth Day Awareness: Hospitals Embrace Sustainability Efforts
2024-04-22
WHO Raises Alarm: Bird Flu Threat to Humans an ‘Enormous Concern’
2024-04-19
The Legal Battlefield of Weight-Loss Drugs: Eli Lilly and Novo Nordisk on the Defensive
2024-04-18
Pharmacogenomics in Asia-Pacific: Nalagenetics CEO Levana Sani Offers Insights and Strategies
2024-04-17
EVENT
2024-04-27
2024 Biomedical Final Pitch Competition
Room DA1620, Dana Building, Dana-Farber Cancer Institute, 99 Jimmy Fund Way, Boston, MA 02115
Scroll to Top